4/A: Nuvation Bio Inc. Director Option Grant Correction

Nuvation Bio Inc. files an amended Form 4 to correct an administrative error in the reporting of stock options granted to Director Xiangmin Cui.

Summary

• This filing is an amendment to a previously filed Form 4 by Nuvation Bio Inc. Director, Xiangmin Cui.
• The amendment corrects an administrative error regarding the number of stock options granted on February 27, 2026.
• The original filing incorrectly reported 74,813 options; the corrected number of options granted is 76,923.
• These options are for Class A Common Stock with an exercise price of $5.91.
• The options vest monthly over 24 months, starting one month after January 1, 2026, contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily an administrative correction with no new financial information or strategic shifts.

Positives

• Correction of an administrative error ensures accurate reporting of beneficial ownership.
• The grant of options to a director indicates continued alignment of management and shareholder interests.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The initial error in reporting highlights a potential lapse in internal controls or review processes for SEC filings.

Risks

• Potential for further administrative errors in SEC filings.
• The vesting schedule is subject to continuous service, meaning the director could forfeit unvested options if service is terminated.

Future Outlook

The filing does not contain forward-looking statements or guidance; it is a correction of a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for insider transactions and amendments are common to correct reporting errors. The correction of option grant numbers is a routine administrative adjustment.

Stakeholder Impact

• Shareholders: Increased transparency and accuracy regarding director equity holdings.

Next Steps

• Ensure accurate record-keeping and reporting of all future transactions and grants.

Key Dates

Keywords

Form 4, SEC Filing, Nuvation Bio Inc., NUVB, Stock Options, Beneficial Ownership, Director, Amendment, Class A Common Stock, Vesting Schedule